Contents

Preface ......................................................................................................................v

Contents of Volume I ............................................................................................ xiii

Contributors .......................................................................................................... xviii

PART I. INTRODUCTION
1 Molecular and Genetic Aspects of Lung Cancer
   William N. Rom and Kam-Meng Tchou-Wong .................................................. 3

PART II. DETECTION OF ALTERED TUMOR MARKERS IN CLINICAL SAMPLES
   FOR DIAGNOSIS AND PROGNOSIS
A. MOLECULAR METHODS FOR PROGNOSTIC DETECTION OF ALTERED TUMOR
   MARKERS: CLINICAL IMPLICATIONS
2 Molecular Alterations in Lung Cancer: Impact on Prognosis
   Takashi Kijima, Gautam Maulik, and Ravi Saigia ............................................. 29
3 Cellular Predictive Factors of Drug Resistance
   in Non-Small Cell Lung Carcinomas
   Manfred Volm, Reet Koomägi, and Werner Rittgen ......................................... 39
4 Clinical Implications of p53 Mutations in Lung Cancer
   Barbara G. Campling and Wafik S. El-Deiry .................................................. 53
5 An Epidemiologic and Clinicopathologic Overview
   of AIDS-Associated Pulmonary Kaposi’s Sarcoma
   David M. Aboulafia ....................................................................................... 79
6 Myeloperoxidase Promoter Region Polymorphism
   and Lung Cancer Risk
   Xifeng Wu, Matthew B. Schabath, and Margaret R. Spitz ............................ 121
7 Clinical Utility of Tumor Markers in the Management
   of Non-Small Cell Lung Cancer
   Dennis E. Niewoehner and Jeffrey B. Rubins ............................................... 135
B. Molecular Methods for Prognostic Detection of Altered Lung Tumor Markers in Clinical Samples

I. DNA-Based Analysis

8 Detection of Chromosomal Aberrations in Lung Tissue and Peripheral Blood Lymphocytes Using Interphase Fluorescence in Situ Hybridization (FISH)
Randa A. El-Zein and Sherif Z. Abdel-Rahman ........................................ 145

9 In Situ Analysis of Telomerase RNA Gene Expression as a Marker for Tumor Progression
W. Nicol Keith ..................................................................................... 163

10 A High-Throughput Methodology for Identifying Molecular Targets Overexpressed in Lung Cancers
Tongtong Wang and Steven G. Reed .............................................. 177

11 Expression Profiling of Lung Cancer Based on Suppression Subtraction Hybridization (SSH)
Simone Petersen and Iver Petersen ................................................... 189

12 Comparative Genomic Hybridization of Human Lung Cancer
Iver Petersen ...................................................................................... 209

13 Sensitive Assays for Detection of Lung Cancer: Molecular Markers in Blood Samples
Marcia V. Fournier, Katherine J. Martin, Edgard Graner, and Arthur B. Pardee ......................................................... 239

14 Fluorescent Microsatellite Analysis in Bronchial Lavage as a Potential Diagnostic Tool for Lung Cancer
John K. Field and Triantafillos Liloglou ........................................... 251

15 Southern Blotting of Genomic DNA from Lung and Its Tumors: Application to Analysis of Allele Loss on Chromosome 11p15.5
Diana M. Pitterle and Gerald Bepler ................................................... 263

16 Assessment of Insulin-Like Growth Factors and Mutagen Sensitivity as Predictors of Lung Cancer Risk
Xifeng Wu, He Yu, Nimisha Makan, and Margaret R. Spitz ............ 279

II. PCR-Based Analyses

17 Comparative Multiplex PCR and Allele-Specific Expression Analysis in Human Lung Cancer: Tools to Facilitate Target Identification
Jim Heighway, Daniel Betticher, Teresa Knapp, and Paul Hoban ......................................................... 291

18 Detection of K-ras Point Mutations in Sputum from Patients with Adenocarcinoma of the Lung by Point-EXACCT
Veerle A. M. C. Somers and Frederick B. J. M. Thunnissen ........... 305
Contents ix

19 Detection of K-ras and p53 Mutations by “Mutant-Enriched” PCR-RFLP
Marcus Schuermann ................................................................. 325

20 Detection of Small Cell Lung Cancer by RT-PCR for Neuropeptides, Neuropeptide Receptors, or a Splice Variant of the Neuron Restrictive Silencer Factor
Judy M. Coulson, Samreen I. Ahmed, John P. Quinn, and Penella J. Woll ................................................................. 335

III. Immunohistochemical Analyses
21 Utilization of Thyroid Transcription Factor-1 Immunostaining in the Diagnosis of Lung Tumors
Nelson G. Ordóñez ................................................................. 355

22 Molecular Biologic Substaining of Stage I NSCLC Through Immunohistochemistry Performed on Formalin-Fixed, Paraffin-Embedded Tissue
Mary-Beth Moore Joshi, Thomas A. D’Amico, and David H. Harpole, Jr. ................................................................. 369

23 A Sensitive Immunofluorescence Assay for Detection of p53 Protein in the Sputum
Zumei Feng, Defa Tian, and Radoslav Goldman ......................... 389

24 SPR1: An Early Molecular Marker for Bronchial Carcinogenesis
Derick Lau, Linlang Guo, Andrew Chan, and Reen Wu ............... 397

25 Determination of Biological Parameters on Fine-Needle Aspirates from Non-Small Cell Lung Cancer
Cecilia Bozzetti, Annamaria Guazzi, Rita Nizzoli, Nadia Naldi, Vittorio Franciosi, and Stefano Cascinu .................................. 405

IV. Imaging Analysis
26 Detection and Analysis of Lung Cancer Cells from Body Fluids Using a Rare Event Imaging System
Stine-Kathrein Kraeft, Ravi Salgia, and Lan Bo Chen .................. 423

27 Reconstruction of Geno-Phenotypic Evolutionary Sequences from Intracellular Patterns of Molecular Abnormalities in Human Solid Tumors
Stanley E. Shackney, Charles A. Smith, Agnese A. Pollice, and Jan F. Silverman .......................................................... 431

PART III. NOVEL THERAPIES
A. INTRODUCTION TO CURRENT TREATMENTS
28 Surgical Treatment of Lung Cancer: Past and Present
Clifton F. Mountain and Kay E. Hermes ....................................... 453
Recent Advances and Dilemmas in the Radiotherapeutic Management of Locally Advanced Non-Small Cell Lung Cancer

Benjamin Movsas ................................................................. 489

Photodynamic Therapy in Lung Cancer: A Review

David Ost .................................................................................. 507

B. GENE THERAPIES

I. Overview: Advantages and Pitfalls of Lung-Targeted Gene Therapies

Gene Therapy for Lung Cancer: An Introduction
Eric B. Haura, Eduardo Sotomayor, and Scott J. Antonia ........... 529

Identifying Obstacles to Viral Gene Therapy for Lung Cancer:
Malignant Pleural Effusions as a Paradigm
Raj K. Batra, Raymond M. Bernal, and Sherven Sharma ............. 545

Topical Gene Therapy for Pulmonary Diseases with PEI-DNA Aerosol Complexes

II. Plasmid and Virus-Based Gene Therapies

Targeted Delivery of Expression Plasmids to the Lung via
Macroaggregated Polyethyleneimine-Albumin Conjugates
Frank M. Orson, Berma M. Kinsey, Balbir S. Bhogal, Ling Song, Charles L. Densmore, and Michael A. Barry........... 575

Preparation of Retroviral Vectors for Cell-Cycle-Targeted Gene Therapy of Lung Cancer
Pier Paolo Claudio and Antonio Giordano .................................. 591

Aerosol Gene Therapy for Metastatic Lung Cancer Using PEI-p53 Complexes
Ajay Gautam, J. Clifford Waldrep, Eugenie S. Kleinerman, Bo Xu, Yuen-Kai Fung, Anne T’Ang, and Charles L. Densmore ......................................................... 607

III. Antisense Oligonucleotide Gene Therapies

Clinical Development of Antisense Oligonucleotides as Anti-Cancer Therapeutics
Helen X. Chen ............................................................................. 621

Antisense Oligonucleotides Targeting Rho Subunit of Protein Kinase A:
In Vitro and In Vivo Anti-Tumor Activity and Pharmacokinetics
Ruiven Zhang and Hui Wang ....................................................... 637
Contents

39 Use of Antisense Oligonucleotides for Therapy: Manipulation of Apoptosis Inhibitors for Destruction of Lung Cancer Cells
   Siân H. Leech, Robert A. Olie, and Uwe Zangemeister-Wittke .... 655
40 Induction of Programmed Cell Death with an Antisense Bcl-2 Oligonucleotide
   Patrick P. Koty, Wendong Lei, and Mark L. Levitt ................. 671
C. IMMUNE THERAPIES
41 Tumor Vaccination with Cytokine-Encapsulated Microspheres
   Nejat K. Egilmez, Yong S. Jong, Edith Mathiowitz, and Richard B. Bankert ........................................... 687
42 Adoptive Immunotherapy
   Julian A. Kim and Suyu Shu .................................................. 697
43 Intratumoral Therapy with Cytokine Gene-Modified Dendritic Cells in Murine Lung Cancer Models
   Sherven Sharma, Seok Chul Yang, Raj K. Batra, and Steven M. Dubinett ........................................... 711
44 Cyclooxygenase 2-Dependent Regulation of Antitumor Immunity in Lung Cancer
   Sherven Sharma, Min Huang, Mariam Dohadwala, Mehis Pold, Raj K. Batra, and Steven M. Dubinett .......... 723
D. CHEMOPREVENTION
45 Chemoprevention of Lung Cancer
   Hanspeter Witschi ................................................................. 739
46 Assessing the Interaction of Particulate Delivery Systems with Lung Surfactant
   Timothy Scott Wiedmann ....................................................... 755
47 Chemopreventive Therapeutics: Inhalation Therapies for Lung Cancer and Bronchial Premalignancy
   Missak Haigentz, Jr. and Roman Perez-Soler ....................... 771
Index ............................................................................................... 781
Lung Cancer
Volume 2: Diagnostic and Therapeutic Methods and Reviews
Driscoll, B. (Ed.)
2003, XXIII, 816 p., Hardcover
A product of Humana Press